Research project for a Master's or PhD student in Virology and Immunology :
The main focus of Dr Lamarre’s laboratory is to understand the mechanisms that permit the establishment of viral persistence both from the host and virus perspectives. We are particularly interested in characterizing the correlates of protection against the hepatitis C virus. Our research program is divided in three main projects: 1. Understanding the role of natural antibodies in promoting acquired immune responses to persisting viruses. 2. Characterizing the mechanisms involved in the establishment of viral persistence focusing primarily on the neutralizing antibody response. 3. Developing a novel vaccination platform against chronic viral infections based on plant virus-like particles. Our long-term goal is to increase our understanding of HCV pathogenesis and immunogenicity in order to potentially improve treatment and prevention of this and other important chronic viral infections.
Dr. Alain Lamarre obtained his B.Sc. from the department of Biological Sciences (1988) at the Université de Montréal and his Ph.D. in Virology and Immunology (1996) from Institut Armand-Frappier. After postdoctoral training in Virology and Immunology at the Institute of Experimental Immunology in Zurich, Switzerland in the laboratory of Profs. Hans Hengartner and Rolf Zinkernagel he joined the INRS-Institut Armand-Frappier in 2002. He was a CIHR New Investigator Award recipient from 2002 to 2007 and currently holds the Jeanne and J.-Louis Lévesque chair in Immunovirology from the J.-Louis Lévesque Foundation.
The research interests of his laboratory, funded by CIHR and NSERC, are aimed at a better understanding of the mechanisms responsible for viral persistence with the ultimate goal of improving the treatment and prevention of chronic viral infections.
// 4 décembre 2017
Club de recherches cliniques du Québec
// 30 octobre 2017
Interactions hôtes-agents pathogènes
// 7 février 2017
Gène associé à un trouble des glandes
// 11 janvier 2017
Mise en évidence du rôle des IFN-I
// 23 mars 2016
Nanoparticule et traitement du cancer
Dans les médias
// 8 février 2017
// 7 février 2017
// 17 janvier 2017
// 16 janvier 2017
Consultez notre webzine